If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Directorate Changes

24 Oct 2014 07:00

RNS Number : 1755V
Imperial Innovations Group plc
24 October 2014
 



24 October 2014

 

Imperial Innovations Group plc

 

Directorate Changes

 

Imperial Innovations Group plc (AIM: IVO or 'the Group', 'Innovations') announces that its non-executive director Dr Paul Atherton will not be seeking re-election at the Group's AGM on 16 December 2014 and will step down from the Board as of that date.

 

Dr Atherton was appointed to the Board on 29 April 2006, having been a director of the Group's subsidiary Imperial Innovations Ltd since September 2004. Dr Atherton currently serves on the Nomination Committee of the Board and previously served on its Remuneration and Audit Committees.

 

Separately, in accordance with its policy of voluntary compliance with the UK Corporate Governance Code, the Group has appointed non-executive director Linda Wilding to the role of Senior Independent Director with immediate effect.

 

Martin Knight, Chairman of Imperial Innovations, said:

 

"On behalf of the Board I would like to thank Paul for his ten years of service, during which he has played an important and influential role in the evolution of the Group. His experience as a successful scientific entrepreneur and the chairman of technology businesses has ensured that the perspective of founders and managers remains central to our way of doing business.

 

"In addition to his role on the board of Innovations, Paul co-founded and chaired two of our spin-out companies. Midaz Lasers was successfully sold to Coherent Inc. in 2012, and Paul continues as the chairman of Nexeon, our largest unquoted investment.

 

"We look forward to continuing to work together with Paul and thank him for the significant contribution he has made to Innovations over many years."

 

For further information contact:

 

Imperial Innovations Group plc

020 3053 8834

Martin Knight, Chairman

Jon Davies, Director of Communications

 

Instinctif Partners

020 7457 2020

Adrian Duffield/Melanie Toyne-Sewell

 

J.P. Morgan Cazenove (Nominated Adviser)

020 7742 4000

Michael Wentworth-Stanley/Alec Pratt

 

Cenkos Securities

020 7397 8900

Andy Roberts/Christopher Golden

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAEAKEDASPLFFF
Date   Source Headline
30th May 20147:00 amRNSVeryan announces results on two-year Mimics study
22nd May 20147:00 amRNSYoyo closes £2.8 million seed investment round
6th May 20142:45 pmRNSHolding(s) in Company
24th Apr 20147:00 amRNSNexeon completes manufacturing facility
14th Apr 201412:00 pmRNSDirector change
3rd Apr 20143:36 pmRNSDirector's share purchase
28th Mar 20147:01 amRNSHalf Yearly Report
13th Mar 20141:04 pmRNSNotice of Results
13th Mar 20147:01 amRNSCircassia announces offer price
26th Feb 20147:40 amRNSCircassia indicative pricing notification
6th Feb 20147:03 amRNSCircassia announces intention to float
28th Jan 20147:00 amRNSAppointment of Joint Broker
7th Jan 20147:00 amRNSCell Medica achieves EU orphan drug designation
30th Dec 201310:00 amRNSFurther investment in TopiVert
18th Dec 20137:00 amRNS£5.1m funding round for Econic Technologies
17th Dec 201312:32 pmRNSResult of AGM
17th Dec 20139:00 amRNS£17.5m funding round for Crescendo Biologics
11th Dec 20137:00 amRNSIXICO launches first CE marked device
10th Dec 20137:00 amRNSSeed funding round for Cambridge spinout Aqdot
6th Dec 20137:00 amRNSGrant of share options
22nd Nov 20133:24 pmRNSOxford Immunotec trading commences on NASDAQ
20th Nov 20139:25 amRNSPulmocide receives £17m Series A funding
18th Nov 20137:00 amRNSMISSION Therapeutics receives £20m funding
16th Oct 20137:01 amRNSOxford Immunotec makes public S1 for potential IPO
16th Oct 20137:00 amRNSBoard Changes
16th Oct 20137:00 amRNSFinal Results
1st Oct 20139:00 amRNSCircassia grass allergy treatment success
26th Sep 20137:00 amRNSCell Medica opens commercial facility in Germany
23rd Sep 20137:05 amRNSIXICO expands into digital healthcare
23rd Sep 20137:00 amRNSProposed acquisition of IXICO Limited
20th Sep 20139:00 amRNSNotice of Results
12th Sep 20137:00 amRNSCircassia phase II clinical study success
10th Sep 20137:00 amRNSLeads £8m funding round in Plaxica
29th Aug 20137:00 amRNSInvestment in new mobile payments business
12th Aug 20136:01 pmRNSDirector/PDMR Shareholding
26th Jul 20138:45 amRNSPortfolio company PolyTherics merges with Antitope
17th Jul 20137:00 amRNSDirectorate Change
2nd Jul 20137:00 amRNS£30m loan from EIB for healthcare investment
25th Jun 20137:00 amRNSInvestment in PsychologyOnline
4th Jun 20137:00 amRNSAutifony starts phase I trial
8th May 20137:00 amRNSCell Medica treats first patient in new trial
29th Apr 20137:00 amRNSInvestment team appointment
17th Apr 20139:26 amRNSBoard change
22nd Mar 20137:00 amRNSHalf year results
1st Mar 20139:22 amRNSNotice of Results
1st Mar 20138:38 amRNSNotification of major interest in shares
25th Feb 20137:00 amRNSCircassia's cat allergy treatment
14th Feb 20137:00 amRNSInvestment in new technology company
23rd Jan 20137:00 amRNS£1.5m investment in new software portfolio company
21st Jan 20133:45 pmRNSListing of shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.